Evommune
Market cap $290M 41.3M shares (10-Q, Nov 10, 2026) × $7.02 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- EVO301 corporate update2H 2026EVO301 corporate update, 2H 2026, routine
- EVO570 corporate update~Jan 2027EVO570 corporate update, ~Jan 2027, routine
- EVO301 Ph2b startMid-2027EVO301 Ph2b start, Mid-2027, routine
- EVO756 toplineJul 16, 2027EVO756 topline, Jul 16, 2027, major
- EVO646 Ph1 readoutLate 2027EVO646 Ph1 readout, Late 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
EVO301
EVO570
HC118 · HP570EVO646
- Undisclosed indication
Technology platforms
SAFAbody · AprilBio Co., Ltd.
SAFA (Anti-Serum Albumin Fab-Associated) fusion protein platform enabling half-life extension via FcRn-mediated recycling of human serum albumin and efficient tissue distribution due to smaller molecular size (~65 kDa); used to engineer EVO301 as a long-acting IL-18BP therapeutic for inflammatory diseases including atopic dermatitis and ulcerative colitis
Targets: IL-18BP, HSA
Discontinued (2)
- EVO756 — Chronic Spontaneous Urticaria · trial did not meet primary endpoint; company decided to cease development of EVO756 for CSU
- EVO756 — Atopic Dermatitis · missed primary endpoint in Phase 2b
Capital (as filed)
- Cash
- $47.6M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $121M Sep 30, 2026
- Long-term investments
- $93.6M Sep 30, 2026
- Operating cash flow
- −$25.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $262M cash, runway 2H 2029 per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Offering documents (5)
- 2026-11-04 424B3 · Offering document incl. pre-funded warrants
- 2026-09-09 424B3 · Prospectus supplement
- 2026-08-06 424B3 · Prospectus supplement
- 2026-06-29 424B3 · Prospectus supplement
- 2026-06-02 424B3 · Prospectus supplement
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (7)
- 2026-11-13 UPDATE: Evommune (EVMN) - The Cash Floor Gets Left Behind 🔒 Paid
- 2026-11-05 UPDATE: Evommune (EVMN) - A Third Shot, Paid for in Shares 🔒 Paid
- 2026-10-01 UPDATE: Evommune (EVMN) - The Last Shot Standing Shows Its Numbers 🔒 Paid
- 2026-09-09 UPDATE: Evommune (EVMN) - The Second Shot Misses Too 🔒 Paid
- 2026-08-07 UPDATE: Evommune (EVMN) - The Clock Moves Up to September 🔒 Paid
- 2026-06-30 UPDATE: Evommune (EVMN) — The CSU Shot Misses 🔒 Paid
- 2026-05-22 Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (7 calls)
Every verdict Biotech Distilled has published on Evommune, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-05-22 Watch Evommune (EVMN) — Scientific Deep Dive for EVO756, EVO301 and Pipeline Products Strong science and smart-money cap table, but the June CSU binary is too high-risk to size into without pre-binary trim discipline, and licensed economics cap upside.
- 2026-06-30 Avoid UPDATE: Evommune (EVMN) — The CSU Shot Misses EVO756 missed the CSU primary endpoint at every dose, zeroing the lead value driver; mechanism failed its cleanest randomized test and read-across to remaining indications is now negative.
- 2026-08-07 Avoid UPDATE: Evommune (EVMN) - The Clock Moves Up to September AD readout dated for September but mechanism failed its cleanest test, dose ceiling keeps falling, and no catalyst justifies re-entry ahead of the print.
- 2026-09-09 Avoid UPDATE: Evommune (EVMN) - The Second Shot Misses Too EVO756 missed AD primary and all secondaries at every dose; two randomized Phase 2b failures confirm a mechanism story not a dose story, leaving only a lottery-ticket migraine trial and EVO301 a year from data.
- 2026-10-01 Watch UPDATE: Evommune (EVMN) - The Last Shot Standing Shows Its Numbers EVO301 posted a statistically clean placebo-controlled EASI signal at EADV with consistent secondaries and clean safety, while the stock trades near cash, making the pipeline effectively free.
- 2026-11-05 Watch UPDATE: Evommune (EVMN) - A Third Shot, Paid for in Shares In-licensing EVO570 (VAV1 molecular glue degrader) broadens the pipeline cheaply but adds a preclinical asset with no human data; stock still trades near cash so watch list is maintained without upgrade.
- 2026-11-13 Watch UPDATE: Evommune (EVMN) - The Cash Floor Gets Left Behind Q3 cash confirmed and Phase 2b design disclosed, but the stock has run 33% above the PIPE price and now prices in pipeline value, reducing the margin of safety that made the watch-list setup compelling.
- Avoid call · opened Jun 30, 2026 at $13.29 · closed Oct 2, 2026 (downgraded to WATCH from avoid) at $6.92 · -47.9% vs XBI -2.4%
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“Our Phase 2b dose-ranging trial of EVO756 in moderate-to-severe AD was initiated in August 2025, and we expect to report initial results in September 2026.”
matched to EVO756 · topline data
-
-
-
“Phase 2b Top-Line Data Readout in AD Expected Next Month: The Company expects to report top-line data in September 2026 for the fully-enrolled Phase 2b dose-ranging clinical trial (N=120) in moderate-to-severe AD patients.”
matched to EVO756 · topline data
-
-
-
“Our Phase 2b dose-ranging trial of EVO756 in moderate-to-severe AD was initiated in August 2025, and we expect to report initial results in September 2026.”
matched to EVO756 · topline data
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (42)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 20268-KCurrent report: officer / director change
- Nov 17, 2026424B3Prospectus (resale / update)
- Nov 12, 2026ReleaseEvommune Reports Third Quarter 2026 Financial Results and Provides Business Highlights→ BD update
- Nov 12, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1→ BD update
- Nov 12, 2026424B3Prospectus (resale / update)→ BD update
- Nov 12, 202610-QQuarterly report→ BD update
- Nov 10, 2026SCHEDULE 13D/A13D amendment
- Nov 9, 2026ReleaseEvommune to Present at Upcoming Investor Conferences
- Nov 5, 2026ReleaseEvommune Announces Webcast Discussing EVO570 and Its Expanding Immunology Portfolio Today at 8:30 a.m. ET
- Nov 5, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Nov 4, 2026ReleaseEvommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals→ BD updateSummary on the 8-K
- Nov 4, 2026ReleaseEvommune Announces $30 Million Private Placement→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1→ BD updateEvommune just reloaded the pipeline with a licensed VAV1 molecular glue degrader (EVO570) showing ~20× greater preclinical potency than Novartis's MRT-6160, backed by a $30M PIPE at current prices from OrbiMed, Adage, and Balyasny — a meaningful signal that institutional money is re-engaging the story after two EVO756 failures.
- Nov 4, 2026424B3Prospectus (resale / update)→ BD updateSummary on the 8-K
- Oct 1, 2026ReleaseEvommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress→ BD updateSummary on the 8-K
- Oct 1, 20268-KCurrent report: Reg FD disclosure · EX-99.1→ BD updateThe full EVO301 Phase 2a dataset just landed at EADV: 55% EASI reduction vs. 22% placebo (p<0.01), responses still deepening 8 weeks after the last of only two doses, and a safety profile cleaner than any approved AD biologic — but the stock is down ~45% since the September AD miss and the Phase 2b is still a year away.BD extracted 1 program update from this document → EVMN pipeline
- Sep 23, 2026ReleaseEvommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
- Sep 23, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Sep 15, 20268-KCurrent report: Reg FD disclosure · EX-99.1BD extracted 2 program updates from this document → EVMN pipeline
- Sep 9, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → EVMN pipeline
- Sep 9, 2026424B3Prospectus (resale / update)
- Sep 8, 2026ReleaseEvommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis→ BD updateBD extracted 2 program updates from this document → EVMN pipeline
- Aug 6, 2026ReleaseEvommune Reports Second Quarter 2026 Financial Results and Provides Business HighlightsBD extracted 1 program update from this document → EVMN pipeline
- Aug 6, 20268-KCurrent report: results of operations · EX-99.1
- Aug 6, 2026424B3Prospectus (resale / update)
- Aug 6, 202610-QQuarterly reportBD extracted 1 program update from this document → EVMN pipeline
- Jul 30, 2026ReleaseEvommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
- Jul 30, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Jun 29, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1
- Jun 29, 2026424B3Prospectus (resale / update)
- Jun 2, 20268-KCurrent report: shareholder vote
- Jun 2, 2026424B3Prospectus (resale / update)
- May 7, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- May 7, 2026424B3Prospectus (resale / update)
- May 7, 202610-QQuarterly report
- Apr 24, 2026424B3Prospectus (resale / update)
- Apr 21, 2026DEFA14AProxy soliciting material
- Apr 21, 2026DEF 14AProxy statement
- Apr 17, 2026S-1Registration statement
- Apr 13, 20268-KCurrent report: Reg FD disclosure · EX-99.1
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1
- Mar 5, 202610-KAnnual report
10 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13G/A13G amendment
- Aug 14, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 16, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 24, 2026EFFECTRegistration effective
- Apr 22, 2026UPLOADUPLOAD
- Apr 22, 2026CORRESPCORRESP
- Apr 21, 2026ARSAnnual report to shareholders
- Mar 5, 2026S-8Employee plan registration